Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Natalie M Mount

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences|September 30, 2015
Cell-based therapy technology classifications and translational challengesNatalie M Mount, Stephen J Ward, Panos Kefalas, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 6, 2011
Preclinical and clinical pharmacokinetics of PF-02413873, a nonsteroidal progesterone receptor antagonistPeter J Bungay, Sarah Tweedy, David C Howe, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 19, 2011
The translational efficacy of a nonsteroidal progesterone receptor antagonist, 4-[3-cyclopropyl-1-(mesylmethyl)-5-methyl-1H-pyrazol-4-yl]oxy,-2,6-dimethylbenzonitrile (PF-02413873), on endometrial growth in macaque and humanDavid C Howe, Natalie M Mount, Kirsty Bess, et al.
Journal of Medicinal Chemistry|June 9, 2006
A novel series of potent and selective PDE5 inhibitors with potential for high and dose-independent oral bioavailabilityCharlotte M N Allerton, Christopher G Barber, Kevin C Beaumont, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences|September 30, 2015
Cell-based therapy technology classifications and translational challengesNatalie M Mount, Stephen J Ward, Panos Kefalas, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 6, 2011
Preclinical and clinical pharmacokinetics of PF-02413873, a nonsteroidal progesterone receptor antagonistPeter J Bungay, Sarah Tweedy, David C Howe, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 19, 2011
The translational efficacy of a nonsteroidal progesterone receptor antagonist, 4-[3-cyclopropyl-1-(mesylmethyl)-5-methyl-1H-pyrazol-4-yl]oxy,-2,6-dimethylbenzonitrile (PF-02413873), on endometrial growth in macaque and humanDavid C Howe, Natalie M Mount, Kirsty Bess, et al.
Journal of Medicinal Chemistry|June 9, 2006
A novel series of potent and selective PDE5 inhibitors with potential for high and dose-independent oral bioavailabilityCharlotte M N Allerton, Christopher G Barber, Kevin C Beaumont, et al.
Pageof 1